Metformine Hcl Aurobindo

Metformin, the active ingredient in Metformine Hcl Aurobindo, is a biguanide presented as an oral dosage form for oral use. It is used to lower elevated blood glucose levels in patients with type 2 diabetes mellitus and related glucose‑handling disorders.

GNH USA supplies Metformine Hcl Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin is indicated for conditions that involve impaired glucose regulation within the type 2 diabetes therapeutic pathway.

Type 2 diabetes mellitus: reduces fasting and post‑prandial blood glucose levels. Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes. Polycystic ovary syndrome (off‑label use): improves insulin sensitivity and may aid menstrual regularity.

Metformin is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Gastrointestinal upset (nausea, abdominal discomfort) - Diarrhea - Metallic taste in the mouth - Loss of appetite - Mild weight loss

Serious or Rare Side Effects: - Lactic acidosis (rare but potentially fatal) - Severe hypoglycemia when combined with other glucose‑lowering agents - Hepatotoxicity (very rare) - Skin rash or hypersensitivity reactions

Metformin should be used with awareness of specific safety considerations.

Renal function assessment: avoid use in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²). Lactic acidosis risk: discontinue before any radiologic contrast studies involving iodine. Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation. Alcohol consumption: limit intake as excessive alcohol may increase lactic acidosis risk. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Metformin may interact with several medicines that affect its plasma concentration or increase the risk of adverse events.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure and lactic acidosis. - Cimetidine: may increase metformin plasma levels. - Certain antiretrovirals (e.g., didanosine): heightened risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics (especially thiazides): can raise blood glucose. - ACE inhibitors or ARBs: monitor renal function when combined.